Finland cancer survival rates are lagging behind the other Nordic countries across a striking number of cancer types, according to a new investigation by Yle’s MOT unit based on Nordic registry data. The gap does not apply to every tumour, and Finland still performs well in areas such as breast and prostate cancer. But in many other cancers, including lung cancer, the country now trails Sweden, Norway, Denmark and, in some cases, Iceland. What is drawing growing concern is not only the outcome gap itself, but how little broad public debate it has triggered.
The Nordic cancer comparison is worse than many expected
The MOT investigation, drawing on the NORDCAN database, found that Finland ranks last in the Nordic region for around 12 male-specific cancers and for several female-specific cancers as well. According to Yle’s reporting, Finland performs worse than its Nordic peers in cancers including liver cancer, different leukaemias, kidney cancer, laryngeal cancer, cervical cancer, non-Hodgkin lymphoma and multiple myeloma.
The most widely discussed example is lung cancer, where the gap is especially visible. Earlier Nordic comparisons based on NORDCAN data showed that five-year relative survival for men with lung cancer was markedly lower in Finland than in Denmark, Norway and Sweden, while more recent comparative research has again identified Finland as the weakest performer among the Nordic countries. For women, Norway has emerged as the strongest performer, while Finland has remained behind.
This matters because the Nordic countries are often treated as natural benchmarks for one another. They have relatively similar welfare systems, publicly funded healthcare models, high-quality cancer registries and comparable population data. When one country repeatedly falls behind the others, the difference becomes harder to dismiss as statistical noise.
Lung cancer shows how far Finland trails its Nordic peers
The comparative data on lung cancer survival offers one of the clearest illustrations of the gap. In NORDCAN-based research covering 2016–2020, five-year relative survival for men was about 16% in Finland, compared with 24% in Denmark, 26.6% in Norway and 24% in Sweden. Another Nordic study found Norway leading for women too, with five-year survival at 33.2%, while Finland remained behind the other comparison countries.
Yle has also previously reported that, in an earlier Nordic comparison, five-year lung cancer survival in Finland stood at about 13% for men and 19% for women, compared with 19% and 24% in Sweden and 17% and 23% in Denmark. The precise percentages vary depending on the period and methodology used, but the direction is consistent: Finland has not kept pace with the strongest Nordic performers.
At the same time, the picture is not uniformly negative. Finland does comparatively well in breast cancer and prostate cancer treatment, which suggests the issue is not a simple story of systemic collapse. The problem is more uneven and points to weaknesses in diagnosis, access and treatment pathways for specific cancers.
Delayed diagnosis and uneven access may be part of the explanation
No single explanation has yet been proven, and this is itself part of the problem. Yle reported that the deterioration in outcomes and its underlying causes have not been studied extensively in Finland. Even experienced cancer specialists interviewed by the broadcaster said the breadth of the gap came as a surprise.
The factors raised by doctors and researchers are, however, consistent. They include slow access to primary care, difficulties getting symptoms taken seriously early enough, lower use of imaging in some parts of the diagnostic pathway, and later diagnosis after the disease has already spread. In lung cancer, Finnish researchers have pointed to the fact that patients are more often diagnosed only after the cancer has advanced, reducing the chances of surgery and worsening prognosis.
This is where the comparison with the rest of the Nordic region becomes politically sensitive. In systems built on universal care, delays in entering the pathway can be as decisive as what happens inside specialist treatment.
New cancer medicines are another uncomfortable part of the debate
A second issue concerns access to innovative cancer drugs, especially newer immuno-oncology treatments. According to Yle’s investigation, Finland uses these medicines less than many other European countries, despite their growing role in modern cancer care. The country was described as being among the lowest users in Europe.
That does not automatically prove that lower use of these medicines is the main reason for Finland’s weaker outcomes. Cancer survival depends on many variables, from stage at diagnosis to staffing and referral systems. Still, the question is politically difficult because these treatments can cost well above €100,000 per patient, and decisions about who receives them can expose the tension between medical need and budget pressure.
Doctors interviewed by Yle argued that these choices should not remain an unspoken rationing debate inside hospitals. If Finland is implicitly accepting a lower level of treatment than comparable Nordic countries, they said, that should be discussed openly at political level.
Finland’s new cancer strategy admits the country has fallen behind
The issue is no longer confined to media reporting. Finland’s National Cancer Strategy 2026–2035 explicitly states that the country has fallen behind other Nordic countries in outcomes for cancers such as lung cancer and myeloma. The strategy also warns that tighter health and social care budgets threaten timely access to care, even though Finnish cancer treatment costs remain moderate by international standards.
That makes the current moment more consequential. Finland is facing a rising cancer burden, growing treatment costs and a healthcare system under financial pressure. At the same time, the official strategy recognises regional and socioeconomic inequalities in cancer outcomes.
The real issue is not only survival rates, but the lack of open political debate
The most unsettling part of the Finnish debate may be how limited it has been. The public argument has often focused on queues, staffing and healthcare reform in broad terms, while the cumulative effect on cancer survival has received less sustained national attention.
The Nordic comparison changes that. It suggests Finland is not simply struggling with isolated inefficiencies, but with a pattern that can now be measured against its closest peers. Sweden, Norway and Denmark all face their own pressures, yet Finland has still slipped behind them in a range of cancers that are central to public health.
For an international audience, the story matters because it challenges a common assumption: that Nordic healthcare systems are broadly interchangeable in outcomes. They are not. Finland’s cancer data suggests that even among closely related welfare states, differences in access, diagnosis and treatment choices can have life-and-death consequences.
The next question is whether Finland’s political class is ready to discuss that clearly. The data is now harder to ignore, and the silence around it may be becoming part of the problem itself.
